NCT02583204

Brief Summary

The study compares three strategies to prevent/minimise nail problems occuring in women, with breast cancer, undergoing Taxane chemotherapy. The strategies are: application of nail polish and normal care; application of Onicolife drops and normal care and; normal care only.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
105

participants targeted

Target at P50-P75 for not_applicable breast-cancer

Timeline
Completed

Started Oct 2015

Shorter than P25 for not_applicable breast-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 22, 2015

Completed
9 days until next milestone

Study Start

First participant enrolled

October 1, 2015

Completed
21 days until next milestone

First Posted

Study publicly available on registry

October 22, 2015

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2017

Completed
Last Updated

October 22, 2015

Status Verified

October 1, 2015

Enrollment Period

1 year

First QC Date

September 22, 2015

Last Update Submit

October 21, 2015

Conditions

Outcome Measures

Primary Outcomes (2)

  • Nail Assessment Scale

    Evaluate nail interventions (nail polish + standard care Vs Onicolife drops + standard care Vs Standard Care only) that may prevent or minimise the occurrence and severity of nail problems measured using the NToX-G12 (Nail Assessment Scale).

    6 months

  • Adverse Events

    Evaluate nail interventions (nail polish + standard care Vs Onicolife drops + standard care Vs Standard Care only) that may prevent or minimise the occurrence and severity of nail problems measured using Common Terminology Criteria for Adverse Events v3.0 (CTC-AE v3).

    6 months

Secondary Outcomes (3)

  • Quality of Life - NToX-QoL Health related quality of life questionnaire

    6 months

  • Quality of Life - EQ-5D-5L Health related quality of life questionnaire

    6 months

  • Quality of Life-nail grade severity relationship

    6 months

Study Arms (3)

Control - standard care

NO INTERVENTION

Participants will receive standard care regarding nail toxicity. This entails advice to keep nails trim and the provision of a nail oil to massage into the nail daily. Participants will also receive advice in relation to general healthy living.

Intervention - Oncolife drops

EXPERIMENTAL

Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive Onicolife nail drops to be applied twice daily.

Device: Onicolife nail drops

Intervention - Nail polish

EXPERIMENTAL

Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive a dark coloured nail polish to be applied as instructed.

Other: Nail polish

Interventions

The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.

Intervention - Oncolife drops

One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).

Intervention - Nail polish

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • women over the age of 18 years who have been diagnosed with a breast cancer.
  • must be receiving adjuvant or neo-adjuvant Taxotere chemotherapy for breast cancer.
  • participants must be fluent English speakers to be eligible to take part, as there are no resources or additional funding for translators or interpreting services.
  • Participants must provide informed consent.

You may not qualify if:

  • Male patients with a diagnosis of breast cancer
  • Patients who are non-fluent English speakers
  • Patients with a known hypersensitivity reaction to nail/ relevant cosmetic products
  • Previous treatment with taxane chemotherapy with the last two years
  • Patients with only one upper limb.
  • Patients with a neurological deficit to the upper limb (eg, stroke affecting one side)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beatson Oncology Centre

Glasgow, G12 0YN, United Kingdom

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Audrey Morrison, Phd

    NHS Greater Glasgow and Clyde

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 22, 2015

First Posted

October 22, 2015

Study Start

October 1, 2015

Primary Completion

October 1, 2016

Study Completion

April 1, 2017

Last Updated

October 22, 2015

Record last verified: 2015-10

Locations